Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have earned an average rating of “Hold” from the twenty-two research firms that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $124.15.

A number of equities research analysts recently weighed in on ZBH shares. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. BTIG Research reiterated a “buy” rating on shares of Zimmer Biomet in a research report on Monday, April 14th. JMP Securities restated a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 7th. Barclays dropped their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th. Finally, Truist Financial reissued a “hold” rating and set a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th.

Zimmer Biomet Stock Performance

Shares of ZBH opened at $96.38 on Tuesday. The stock has a market capitalization of $19.07 billion, a P/E ratio of 21.66, a P/E/G ratio of 1.95 and a beta of 0.84. The company’s fifty day moving average is $105.87 and its two-hundred day moving average is $106.68. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. Zimmer Biomet has a 1 year low of $93.10 and a 1 year high of $123.96.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the business posted $2.20 EPS. On average, sell-side analysts predict that Zimmer Biomet will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 1.00%. Zimmer Biomet’s payout ratio is 21.57%.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.95% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zimmer Biomet

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZBH. Stonebridge Financial Group LLC purchased a new position in Zimmer Biomet in the fourth quarter valued at about $25,000. Menard Financial Group LLC bought a new stake in shares of Zimmer Biomet in the fourth quarter worth $30,000. Accredited Wealth Management LLC bought a new position in Zimmer Biomet during the 4th quarter valued at $36,000. Kentucky Trust Co bought a new stake in shares of Zimmer Biomet in the 4th quarter worth about $39,000. Finally, OFI Invest Asset Management bought a new position in shares of Zimmer Biomet during the fourth quarter worth about $40,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.